Literature DB >> 15336694

Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands.

K Bushby1, F Muntoni, A Urtizberea, R Hughes, R Griggs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15336694     DOI： 10.1016/j.nmd.2004.05.006

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN： 0960-8966            Impact factor:   4.296


× No keyword cloud information.
  46 in total

Review 1.  Concise review: mesoangioblast and mesenchymal stem cell therapy for muscular dystrophy: progress, challenges, and future directions.

Authors:  Suzanne E Berry
Journal:  Stem Cells Transl Med       Date:  2014-11-12       Impact factor: 6.940

2.  Worsening of cardiomyopathy using deflazacort in an animal model rescued by gene therapy.

Authors:  Ida Luisa Rotundo; Stefania Faraso; Elvira De Leonibus; Gerardo Nigro; Carmen Vitiello; Alessio Lancioni; Daniele Di Napoli; Sigismondo Castaldo; Vincenzo Russo; Fabio Russo; Giulio Piluso; Alberto Auricchio; Vincenzo Nigro
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

Review 3.  What can Duchenne Connect teach us about treating Duchenne muscular dystrophy?

Authors:  Richard T Wang; Stanley F Nelson
Journal:  Curr Opin Neurol       Date:  2015-10       Impact factor: 5.710

Review 4.  Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy.

Authors:  Dominic J Wells
Journal:  J Muscle Res Cell Motil       Date:  2006-07-28       Impact factor: 2.698

5.  Steroid therapy and cardiac function in Duchenne muscular dystrophy.

Authors:  L W Markham; R L Spicer; P R Khoury; B L Wong; K D Mathews; L H Cripe
Journal:  Pediatr Cardiol       Date:  2005 Nov-Dec       Impact factor: 1.655

6.  Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation.

Authors:  Sunil Pradhan; Debabrata Ghosh; Niraj Kumar Srivastava; Ashok Kumar; Balraj Mittal; Chandra Mani Pandey; Uttam Singh
Journal:  J Neurol       Date:  2006-06-19       Impact factor: 4.849

7.  The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used.

Authors:  Craig M McDonald; Erik K Henricson; R Ted Abresch; Jay J Han; Diana M Escolar; Julaine M Florence; Tina Duong; Adrienne Arrieta; Paula R Clemens; Eric P Hoffman; Avital Cnaan
Journal:  Muscle Nerve       Date:  2013-05-16       Impact factor: 3.217

8.  Abnormal circumferential strain is present in young Duchenne muscular dystrophy patients.

Authors:  Thomas D Ryan; Michael D Taylor; Wojciech Mazur; Linda H Cripe; Jesse Pratt; Eileen C King; Kathleen Lao; Michelle A Grenier; John L Jefferies; D Woodrow Benson; Kan N Hor
Journal:  Pediatr Cardiol       Date:  2013-01-29       Impact factor: 1.655

Review 9.  Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy.

Authors:  Alessandra Govoni; Francesca Magri; Simona Brajkovic; Chiara Zanetta; Irene Faravelli; Stefania Corti; Nereo Bresolin; Giacomo P Comi
Journal:  Cell Mol Life Sci       Date:  2013-06-18       Impact factor: 9.261

10.  Regional circumferential strain is a biomarker for disease severity in duchenne muscular dystrophy heart disease: a cross-sectional study.

Authors:  Kan N Hor; Narayan Kissoon; Wojciech Mazur; Resmi Gupta; Richard F Ittenbach; Hussein R Al-Khalidi; Linda H Cripe; Subha V Raman; Michael D Puchalski; William M Gottliebson; D Woodrow Benson
Journal:  Pediatr Cardiol       Date:  2014-08-02       Impact factor: 1.655
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.